Lubrizol Adds Drug Product Manufacturing Capacity

Published on: 

Lubrizol Invests $60 Million to Expand Particle Sciences and Other Facilities in 2017.

The Lubrizol Corporation has announced a $60 million investment in new product solutions, capacity expansion, and additional cGMP manufacturing to strengthen its excipients, polymers, drug formulation, and manufacturing, and medical device contract manufacturing capabilities at the company’s LifeSciences’ global facilities.

The investments, reported in a June 6, 2017 press statement, include additional commercial drug product manufacturing at the company’s Particle Sciences facility in Bethlehem, PA. The facility, which will accommodate sterile and non-sterile products, highly potent compounds, and organic solvent processing, will be adjacent to the existing development and clinical trial manufacturing site. The new space is expected to be operational in the fourth quarter of 2017.

The company also announced expansion of its global facilities for excipients, polymers, and contract manufacturing at multiple sites to increase in-house engineering capacity for medical and pharmaceutical applications.


Source: Particle Sciences